These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30213565)

  • 1. Crystal anisotropy explains structure-mechanics impact on tableting performance of flufenamic acid polymorphs.
    Jain A; Shah HS; Johnson PR; Narang AS; Morris KR; Haware RV
    Eur J Pharm Biopharm; 2018 Nov; 132():83-92. PubMed ID: 30213565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insight into Flufenamic Acid Cocrystal Dissolution in the Presence of a Polymer in Solution: from Single Crystal to Powder Dissolution.
    Guo M; Wang K; Qiao N; Fábián L; Sadiq G; Li M
    Mol Pharm; 2017 Dec; 14(12):4583-4596. PubMed ID: 29091446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative study of solid-state acid-base reactions between polymorphs of flufenamic acid and magnesium oxide using X-ray powder diffraction.
    Chen X; Stowell JG; Morris KR; Byrn SR
    J Pharm Biomed Anal; 2010 Mar; 51(4):866-74. PubMed ID: 19906502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anisotropic crystal deformation measurements determined using powder X-ray diffraction and a new in situ compression stage.
    Haware RV; Kim P; Ruffino L; Nimi B; Fadrowsky C; Doyle M; Boerrigter SX; Cuitino A; Morris K
    Int J Pharm; 2011 Oct; 418(2):199-206. PubMed ID: 21708235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of crystal structure on the tableting properties of n-alkyl 4-hydroxybenzoate esters (parabens).
    Feng Y; Grant DJ; Sun CC
    J Pharm Sci; 2007 Dec; 96(12):3324-33. PubMed ID: 17542021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical Co-Crystal of Flufenamic Acid: Synthesis and Characterization of Two Novel Drug-Drug Co-Crystal.
    Nechipadappu SK; Tekuri V; Trivedi DR
    J Pharm Sci; 2017 May; 106(5):1384-1390. PubMed ID: 28185907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stabilization of metastable flufenamic acid by inclusion of mefenamic acid: solid solution or epilayer?
    Lee EH; Byrn SR
    J Pharm Sci; 2010 Sep; 99(9):4013-22. PubMed ID: 20589947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the compaction of sulfathiazole polymorphs.
    Picker-Freyer KM; Liao X; Zhang G; Wiedmann TS
    J Pharm Sci; 2007 Aug; 96(8):2111-24. PubMed ID: 17565752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of powder X-ray diffraction in studying the compaction behavior of bulk pharmaceutical powders.
    Bandyopadhyay R; Selbo J; Amidon GE; Hawley M
    J Pharm Sci; 2005 Nov; 94(11):2520-30. PubMed ID: 16200547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tableting and tablet properties of alginates: characterisation and potential for Soft Tableting.
    Schmid W; Picker-Freyer KM
    Eur J Pharm Biopharm; 2009 May; 72(1):165-72. PubMed ID: 18992337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative determination of two polymorphic forms of imatinib mesylate in a drug substance and tablet formulation by X-ray powder diffraction, differential scanning calorimetry and attenuated total reflectance Fourier transform infrared spectroscopy.
    Bellur Atici E; Karlığa B
    J Pharm Biomed Anal; 2015 Oct; 114():330-40. PubMed ID: 26099262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissolution Behavior of Flufenamic Acid in Heated Mixtures with Nanocellulose.
    Mantas A; Mihranyan A
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32168901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization and compaction behaviour of nimesulide crystal forms.
    Di Martino P; Censi R; Barthélémy C; Gobetto R; Joiris E; Masic A; Odou P; Martelli S
    Int J Pharm; 2007 Sep; 342(1-2):137-44. PubMed ID: 17583450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aggregate Elasticity, Crystal Structure, and Tableting Performance for p-Aminobenzoic Acid and a Series of Its Benzoate Esters.
    Singaraju AB; Nguyen K; Jain A; Haware RV; Stevens LL
    Mol Pharm; 2016 Nov; 13(11):3794-3806. PubMed ID: 27723351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of physical mixtures and directly compressed tablets of sulfamerazine polymorphs: implications on in vitro release characteristics.
    Roy S; Alexander KS; Riga AT; Chatterjee K
    J Pharm Sci; 2003 Apr; 92(4):747-59. PubMed ID: 12661061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of the microwave technology on solid dispersions of mefenamic acid and flufenamic acid.
    Alshehri S; Shakeel F; Ibrahim M; Elzayat E; Altamimi M; Shazly G; Mohsin K; Alkholief M; Alsulays B; Alshetaili A; Alshahrani A; Almalki B; Alanazi F
    PLoS One; 2017; 12(7):e0182011. PubMed ID: 28759638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating the Influence of Polymers on Supersaturated Flufenamic Acid Cocrystal Solutions.
    Guo M; Wang K; Hamill N; Lorimer K; Li M
    Mol Pharm; 2016 Sep; 13(9):3292-307. PubMed ID: 27494289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular understanding of the compaction behavior of indomethacin polymorphs.
    Khomane KS; More PK; Raghavendra G; Bansal AK
    Mol Pharm; 2013 Feb; 10(2):631-9. PubMed ID: 23301663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal quality and physical reactivity in the case of flufenamic acid (FFA).
    Li H; Wen H; Stowell JG; Morris KR; Byrn SR
    J Pharm Sci; 2010 Sep; 99(9):3839-48. PubMed ID: 20589945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consolidation trend design based on Young's modulus of clarithromycin single crystals.
    Janković B; Skarabot M; Lavrič Z; Ilić I; Muševič I; Srčič S; Planinšek O
    Int J Pharm; 2013 Sep; 454(1):324-32. PubMed ID: 23872226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.